Website for answering vaccination questions for people at high risk for COVID-19
The California Chronic Care Coalition (CCCC), in collaboration with the Healthcare Leadership Council (HLC) and other partner organizations, have launched YourVaccinationGuide.org, a website designed to inform the public about all adult vaccinations including those for COVID-19. The website is aimed at those at high risk for COVID-19 or other diseases but might have concerns about the safety of vaccines for COVID-19 and in general.
The website features a section on COVID-19 vaccines specifically, including frequently asked questions, as well as a general vaccination page containing information on other vaccines recommended for adults and teens. The website is updated with the latest information on COVID-19 vaccines and will also soon be available in Spanish.
Vaccination Rates
To get vaccination statistics for U.S. states, counties, and metropolitan areas in an easily downloadable format, go to the Department of Health and Human Service’s new Community Profile Report page: https://beta.healthdata.gov/Health/COVID-19-Community-Profile-Report/gqxm-d9w9. These reports will help local reporters find COVID-19 data, including information on cases, deaths, PCR tests, hospitalizations, and now, vaccines for communities. For counties and metro areas, the reports include numbers and percentages of people who have been fully vaccinated, reported for the overall population, and those age 65 and older. For states, the reports include more comprehensive information that matches the data available at the CDC’s COVID Data Tracker.
The Vaccination Dashboard hosted at The University of Alabama at Birmingham uses data from the PathCheck Foundation, a global nonprofit dedicated to creating healthy and resilient communities by protecting public health, containing pandemics, and strengthening economies while preserving individual privacy. Found out the latest numbers on worldwide vaccinations, U.S. vaccinations, state vaccinations, vaccine doses available and more.
Pfizer/BioNTech Covid-19 Vaccine Data
The following are links to the published data and ClinicalTrials.gov records for the Pfizer/BioNTech Covid-19 vaccine (BNT162b2):
- FDA EUA document for Pfizier/BioNTech
- FDA Briefing Document with data for Pfizer/BioNTech Covid-19 vaccine
- Pfizer/BioNTech Fact Sheet for Health Providers
- Pfizer/BioNTech Fact Sheet for Recipients and Caregivers
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- Phase I/II study of COVID-19 RNA vaccine BNT162b1 in adults (Aug 2020)
- COVID-19 vaccine BNT162b1 elicits human antibody and TH1 T cell responses (Sept 2020)
- Phase 1/2 Study to Describe the Safety and Immunogenicity of a COVID-19 RNA Vaccine Candidate (BNT162b1) in Adults 18 to 55 Years of Age: Interim Report (preprint, July 2020)
- Here are all other planned or in-progress trials for the Pfizer/BioNTech vaccine at ClinicalTrials-gov.
Moderna Covid-19 Vaccine Data
The following are links to the published data and ClinicalTrials.gov records for the Moderna Covid-19 vaccine (mRNA-1273):
- FDA EUA document for Moderna Covid-19 vaccine
- FDA Briefing Document Addendum for Moderna Covid-19 vaccine
- Moderna Fact Sheet for Health Providers
- Moderna Fact Sheet for Recipients and Caregivers
- Durability of Responses after SARS-CoV-2 mRNA-1273 Vaccination
- Here are all other planned or in-progress trials for the Pfizer/BioNTech vaccine at ClinicalTrials-gov.
Johnson & Johnson Covid-19 Vaccine Data
The following are links to the published data and ClinicalTrials.gov records for the Johnson & Johnson Covid-19 vaccine (BNT162b2):
- FDA Briefing Document for Johnson & Johnson vaccine
- Johnson & Johnson Fact Sheet for Health Providers
- Johnson & Johnson Fact Sheet for Recipients and Caregivers
- Phase 1: Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19
- Safety and immunogenicity of the Ad26.COV2.S COVID-19 vaccine candidate: interim results of a phase 1/2a, double-blind, randomized, placebo-controlled trial (preprint)
- Interim Results of a Phase 1–2a Trial of Ad26.COV2.S Covid-19 Vaccine
- Here are the ClinicalTrials-gov links for the phase 1/2, primary phase 3, additional phase 3, and a phase 3 trial with an adjuvant.
- Here are all other planned or in-progress trials for the Johnson & Johnson vaccine at ClinicalTrials-gov.
AstraZeneca/Oxford Covid-19 Vaccine Data
The following are links to the published data and ClinicalTrials.gov records for the AstraZeneca/Oxford Covid-19 vaccine (ChAdOx1/AZD1222) – not currently authorized in the US:
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults(COV002): a single-blind, randomised, controlled, phase 2/3 trial
- Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
- Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 variant of concern 202012/01 (B.1.1.7): an exploratory analysis of a randomised controlled trial
- Efficacy of the ChAdOx1 nCoV-19 Covid-19 Vaccine against the B.1.351 Variant
- Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
- T cell and antibody responses induced by a single dose of ChAdOx1 nCoV-19 (AZD1222) vaccine in a phase 1/2 clinical trial
- Phase 1/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses
- Here are all other planned or in-progress trials for the AstraZeneca/Oxford vaccine at ClinicalTrials-gov.
The following studies investigate how well the COVID-19 vaccines prevent infection—when a virus enters the body’s cells and begins replicating — aside from simply preventing disease, when symptoms actually occur. While not necessarily exhaustive, these are the majority of studies available on infection prevention of the vaccines through April 20, 2021.
- Moderna mRNA-1273 Sponsor Briefing Document Addendum, Vaccines and Related Biological Products Advisory Committee, 17 December 2020: Data to Support Efficacy Against Asymptomatic Infection.
- Janssen Ad26.COV2.S Vaccine for the Prevention of COVID-19, FDA Briefing Document, pg. 35.
- Initial real world evidence for lower viral load of individuals who have been vaccinated by BNT162b2 (preprint). doi:10.1101/2021.02.08.21251329.
- FDA-authorized COVID-19 vaccines are effective per real-world evidence synthesized across a multi-state health system (preprint). Doi:10.1101/2021.02.15.21251623.
- Effectiveness of BNT162b2 mRNA Vaccine Against Infection and COVID-19 Vaccine Coverage in Healthcare Workers in England, Multicentre Prospective Cohort Study (the SIREN Study)(preprint). Doi:10.2139/ssrn.3790399
- Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients, Lancet. 2021 Mar 6;397(10277):875-877. doi: 10.1016/S0140-6736(21)00448-7.
- Pfizer press release only: Real-world evidence confirms high effectiveness of Pfizer/BioNTech Covid-19 vaccine and profound public health impact of vaccination one year after pandemic declared.
- Initial report of decreased SARS-CoV-2 viral load after inoculation with the BNT162b2 vaccine, Nat Med. 2021 Mar 29. doi: 10.1038/s41591-021-01316-7.
- Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening, Clin Infect Dis. 2021 Mar 10;ciab229. doi: 10.1093/cid/ciab229.
- SARS-CoV-2 Infection after Vaccination in Health Care Workers in California, N Engl J Med. 2021 Mar 23;NEJMc2101927. doi: 10.1056/NEJMc2101927.
- Early Evidence of the Effect of SARS-CoV-2 Vaccine at One Medical Center, N Engl J Med. 2021 Mar 23;NEJMc2102153. doi: 10.1056/NEJMc2102153.
- BNT162b2 mRNA Covid-19 Vaccine Effectiveness among Health Care Workers, N Engl J Med. 2021 Mar 23;NEJMc2101951. doi: 10.1056/NEJMc2101951.
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting, N Engl J Med. 2021 Apr 15;384(15):1412-1423. doi: 10.1056/NEJMoa2101765.
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021, MMWR Morb Mortal Wkly Rep. 2021 Apr 2;70(13):495-500. doi: 10.15585/mmwr.mm7013e3.